X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Efti (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with Bavencio (avelumab) under phase 1 clinical trials forthe treatment of patients with metastatic urothelial carcinoma.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
GEN-001 is being developed as an orally administered microbiome therapeutic with Lactococcus lactis, a single strain bacteria isolated from a healthy human. Its anticancer efficacy was proven by activating immune activity of cancer cells.
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
TILT-123 (igrelimogene litadenorepvec) is a 5/3 chimeric serotype adenovirus armed with two human cytokines, which is being evaluated in combination with avelumab for squamous cell carcinoma of head and neck, and melanoma.
Lead Product(s): Igrelimogene Litadenorepvec,Avelumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
IMP321 (eftilagimod alpha) is a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. It is being investigated in combination with bavencio in metastatic urothelial cancer.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Under the termination, Merck KGaA strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture and commercialize Bavencio (avelumab), from Pfizer. Bavencio is a human PD-L1 antibody used in cancer.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $2,850.0 million Upfront Cash: $850.0 million
Deal Type: Termination March 27, 2023
Details:
VX15/2503 (pepinemab) is a human IgG4 mAb that promotes infiltration and activation of dendritic cells and CD8+ T-cells and reverses immunosuppression within the tumor microenvironment. It is being developed in combination with keytruda for R/M HSNCC.
Lead Product(s): Pepinemab,Avelumab
Therapeutic Area: Oncology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Bavencio (avelumab) is a human PD-L1 antibody. By blocking the interaction of PD-L1 with PD-1 receptors, it has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
The funding will be used to advance to Phase II the company’s combination trials of TILT-123 which use oncolytic immunotherapies synergistically with checkpoint inhibitors.
Lead Product(s): TILT-123,Avelumab
Therapeutic Area: Oncology Product Name: TILT-123
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Finland’s Lifeline Ventures
Deal Size: $23.8 million Upfront Cash: Undisclosed
Deal Type: Financing February 07, 2023
Details:
IOA-244 is a first-in-class semi-allosteric, non-ATP competitive, small molecule PI3Kδ inhibitor which has shown high beneficial tolerability and clinical benefit profile. PI3Kδ over-expression stimulates multiple cancer mechanisms and an oncogenic role in many tumor types.
Lead Product(s): Roginolisib,Avelumab,Pemetrexed
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs).
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
CYNK-101 is a cryopreserved, off-the-shelf, allogeneic, placental CD34+ derived NK cell therapy, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant.
Lead Product(s): CYNK-101,Avelumab
Therapeutic Area: Oncology Product Name: CYNK-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
TG4001 is a therapeutic cancer vaccine candidate using an attenuated and modified poxvirus (MVA) as a vector expressing the HPV16 E6 and E7 proteins (rendered non-oncogenic) interleukin-2.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
It appears that SNK01 might be able to change the tumor microenvironment and suggests that SNK01 plus pembrolizumab has the potential to be a viable therapeutic option for patients with metastatic sarcoma, and especially in PD-L1 negative and low expressing tumors.
Lead Product(s): SNK01,Avelumab
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
BAVENCIO® (avelumab) is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
MRx0518 is single strain Live Biotherapeutic Product (LBP) in development for the treatment of cancer. It is delivered as an oral capsule and stimulates the body’s immune system, directing it to produce cytokines and immune cells that are known to attack tumors.
Lead Product(s): MRx0518,Avelumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
BAVENCIO (avelumab), New analyses of long-term data from study of BAVENCIO as treatment in advanced UC, including data from subgroups defined by best response to first-line chemotherapy and in patients who did or did not receive second-line treatment.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Results will be presented in a poster discussion entitled: Interim analysis of a phase I study of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) and avelumab in advanced refractory sarcoma.
Lead Product(s): SNK01,Avelumab
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
IOA-244 is a PI3Kδ specific, orally dosed, small molecule inhibitor that overcomes tumor and stroma induced immune suppression. Its unique chemistry, semi allosteric binding mode and mechanism of action contribute to its unprecedented clinical profile.
Lead Product(s): Roginolisib,Avelumab,Pemetrexed
Therapeutic Area: Oncology Product Name: IOA-244
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
SNK01 is a first-in-kind, autologous non-genetically modified NK cell therapy with enhanced cytotoxicity which can be consistently produced even from heavily pretreated cancer patients.
Lead Product(s): SNK01,Avelumab
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
In IND-213, HR+/HER2- breast cancer patients treated with Reolysin (pelareorep) and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.
Lead Product(s): Pelareorep,Paclitaxel,Avelumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adlai Nortye
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
PT-112 is first small-molecule conjugate of pyrophosphate in oncology possesses unique pleiotropic mechanism of action promotes immunogenic cell death, induce potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The safety profile for BAVENCIO was consistent with the overall JAVELIN monotherapy clinical development program, with no new safety signals. Patients continued treatment until disease progression, unacceptable toxicity or any other criteria for withdrawal occurred.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2022
Details:
Immutep's lead product candidate, Eftilagimod alpha (IMP321), a soluble LAG-3 fusion protein, which is a first-in-class antigen presenting cell activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Carboplatin,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
Under the terms of the agreement, Imugene will be the sponsor of the study for IMU-131 and will fund the clinical study from existing budgets and resources. Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for the duration of the study.
Lead Product(s): HER-Vaxx,Avelumab
Therapeutic Area: Oncology Product Name: IMU-131
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021
Details:
Data from an investigator-sponsored study of avelumab in combination with neoadjuvant chemotherapy to treat muscle-invasive bladder cancer will be presented for the first time.
Lead Product(s): Avelumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2021
Details:
Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.
Lead Product(s): Aspirin,Avelumab,Lansoprazole
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Manchester
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2021
Details:
Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first quarter of 2022.
Lead Product(s): Aldoxorubicin HCl,Paclitaxel,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2021
Details:
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Avelumab,Chemotherapy Agent
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
Details:
BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody and is part of a class of immunotherapy drugs called immune checkpoint inhibitors.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
Avelumab is being co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer. Exelixis is sponsoring the STELLAR-001 clinical trial, and Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for use in the trial.
Lead Product(s): Encoberminogene Rezmadenovec,Avelumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2021
Details:
The initial Phase Ib/II trial conducted in Europe (France and Spain) has been amended to include a randomized comparison of the combination of TG4001 with avelumab versus avelumab monotherapy in anogenital cancers.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
The collaboration follows in just a year after signing the first agreement with Merck KGaA, Darmstadt, Germany and Pfizer in December 2019 to conduct the first combination clinical trial of avelumab (BAVENCIO®) and GEN-001.
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genome & Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2021
Details:
4D pharma intends to commence a clinical trial in 2021 to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: 4D Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
Details:
4D pharma intends to commence a clinical trial to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Lead Product(s): MRx0518,Avelumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: 4D Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
Details:
The opinion was based on positive findings from the Phase III JAVELIN Bladder 100 trial evaluating BAVENCIO, results of which were published in The New England Journal of Medicine in September.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5% .
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The phase 1 study aims to determine the RP2D (recommended Phase 2 dose) of GEN-001 in combination with BAVENCIO® (avelumab).
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: GEN-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Combination of TG4001 and avelumab demonstrates anti-tumor activity (23.5% overall response rate (ORR)) in patients with previously treated recurrent and/or metastatic HPV-related cancers.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death inducer under Phase 2 development, will be presented at the 32nd Symposium of the EORTC, the National Cancer Institute and the American Association for Cancer Research (AACR).
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
This phase III study sought to determine whether avelumab and concurrent CRT followed by avelumab maintenance could delay progression, as the LA SCCHN recurs in many patients after high-dose, cisplatin-containing, multimodality therapy.
Lead Product(s): Avelumab,Cisplatin
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
Details:
The combination of PT-112 and avelumab was found to be safe and well tolerated in 36 heavily pre-treated solid tumor patients who have exhausted standard therapy options, the majority of whom had received prior immunotherapy.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab. Encouraging early anti-tumour activity signals in a variety of cancer indications not typically sensitive to immune checkpoint inhibitor (ICI) therapy.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
The analysis of the efficacy data from the Phase 1b/2 trial combining TG4001 with avelumab in HPV16-positive recurrent and/or metastatic malignancies showed a promising clinical activity in the overall study population.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
New clinical data from a dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with PD-L1 checkpoint inhibitor avelumab, will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress.
Lead Product(s): Imifoplatin,Avelumab
Therapeutic Area: Oncology Product Name: PT-112
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
FDA has granted permission to amend its existing Phase I trial to add a new cohort of up to 18 patients to be treated with SNK01 in combination with either Pembrolizumab or Avelumab, two established checkpoint inhibitors.
Lead Product(s): Autologous natural killer cells,Avelumab
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Bavencio is an immune checkpoint inhibitor targeting PD-L18 and axitinib is an antiangiogenic VEGF-targeted TKI, their complementary mechanisms of action targeting two key pathways that tumours use to grow.
Lead Product(s): Avelumab,Axitinib
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
Study will evaluate pelareorep's ability to synergistically combine with the checkpoint inhibitor therapy avelumab and improve outcomes in metastatic breast cancer.
Lead Product(s): Pelareorep,Avelumab,Paclitaxel
Therapeutic Area: Oncology Product Name: Kyprolis
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
Company announced preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, demonstrating it’s immune-modulating properties and potentiation by PD-L1 blockade.
Lead Product(s): STRO-002,Avelumab
Therapeutic Area: Oncology Product Name: STRO-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The small phase II study, which is the first trial to explore the use of immunotherapy in patients with GTT, found that 53% of patients responded to therapy, suggesting that avelumab may be a new therapeutic option for these patients.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
